North America Genome Editing Market Size & Outlook
Related Markets
North America genome editing market highlights
- The North America genome editing market generated a revenue of USD 5,056.4 million in 2025.
- The market is expected to grow at a CAGR of 16.6% from 2026 to 2033.
- In terms of segment, crispr/cas9 was the largest revenue generating technology in 2025.
- CRISPR/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 5,056.4 million |
| Market revenue in 2033 | USD 17,158.1 million |
| Growth rate | 16.6% (CAGR from 2026 to 2033) |
| Largest segment | Crispr/cas9 |
| Fastest growing segment | CRISPR/Cas9 |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CRISPR/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
| Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 44.5% of the global genome editing market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,681.5 million by 2033.
Crispr/cas9 was the largest segment with a revenue share of 50.85% in 2025. Horizon Databook has segmented the North America genome editing market based on crispr/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2021 to 2033.
The presence of robust research infrastructure, rise in genetically modified crops, and increase in prevalence of genetic diseases are some of the major driving factors boosting the U.S. genome editing market. Moreover, in the U.S., genetic diseases such as cystic fibrosis are prevalent.
According to the Cystic Fibrosis Foundation Patient Registry, around 30,000 people are suffering from cystic fibrosis in the country. In addition, around 1,000 new cystic fibrosis cases are diagnosed every year. On the other hand, rise in the number of patent approvals for U.S.-based companies has also accelerated the adoption of genome editing tools in the country, leading to positive market growth.
For instance, in May 2020, Merck announced that two CRISPR gene editing patents were approved in the U.S. In September 2020, Editas Medicine revealed that the U.S. Patent and Trademark Office approved certain Broad’s CRISPR/Cas9 patents for priority benefits.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Genome Editing Market Scope
Genome Editing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Precision BioSciences Inc | View profile | 109 | 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, United States, 27701 | https://www.precisionbiosciences.com |
| Recombinetics | View profile | 11-50 | Eagan, Minnesota, United States, North America | https://recombinetics.com/ |
| Origene Technologies | View profile | 501-1000 | Rockville, Maryland, United States, North America | http://www.origene.com |
| Sangamo Therapeutics Inc | View profile | 405 | 501 Canal Boulevard, Richmond, CA, United States, 94804 | https://www.sangamo.com |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | https://www.bluebirdbio.com |
| Horizon Discovery | View profile | 101-250 | Cambridge, Cambridgeshire, United Kingdom, Europe | http://www.horizondiscovery.com |
| Cibus Inc Ordinary Shares - Class A | View profile | 183 | 6455 Nancy Ridge Drive, San Diego, CA, United States, 92121 | https://www.cibus.com |
| Intellia Therapeutics Inc | View profile | 598 | 40 Erie Street, Suite 130, Cambridge, MA, United States, 02139 | https://www.intelliatx.com |
| Editas Medicine Inc | View profile | 226 | 11 Hurley Street, Cambridge, MA, United States, 02141 | https://www.editasmedicine.com |
| CRISPR Therapeutics AG | View profile | 407 | Baarerstrasse 14, Zug, Switzerland, CH-6300 | https://www.crisprtx.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | https://www.cellectis.com |
| New England Biolabs | View profile | 501-1000 | Ipswich, Massachusetts, United States, North America | http://neb.com |
| Genscript Biotech Corp Class H | View profile | 6937 | No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, China, People's Republic of, 211100 | https://www.genscript.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Caribou Biosciences Inc Ordinary Shares | View profile | 137 | 2929 7th Street, Suite 105, Berkeley, CA, United States, 94710 | https://www.cariboubio.com |
| Takara Bio Inc | View profile | 1793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | http://www.takara-bio.co.jp |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
North America genome editing market size, by country, 2021-2033 (US$M)
North America Genome Editing Market Outlook Share, 2025 & 2033 (US$M)
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
